RxSight Inc. Common Stock Earnings Recaps
Q1 2026
May 11, 2026
RxSight shares fell 2.6% post-earnings as investors responded cautiously to persistent volume weakness and elevated operating expenses despite reiteration of full-year guidance.
Key takeaways
- Q1 sales declined 18% year-over-year to $30.9 million, reflecting a decrease in LDD unit volumes, while LAL unit volumes held steady versus the prior year but declined 4% sequentially due to typical seasonality.
- Gross margin improved modestly to 76.1% from 74.8% last year, benefiting from a higher mix of LAL revenue, though full-year gross margin guidance remains lower (70–72%) due to higher cost inventory.
- Operating expenses rose 11% to $31.9 million, driven by investments in expanding commercial and support teams globally.
- Reported net loss was $15.9 million, or $0.38 per share; adjusted net loss was $7.9 million or $0.19 per share, incorporating $7.9 million in stock-based compensation.
- Management reiterated full-year 2026 revenue guidance of $120 million to $135 million and signaled gradual improvement in quarterly growth rates, with international expansion to remain a modest near-term contributor.
Q3 2025
Nov 6, 2025
RxSight's Q3 2025 performance highlighted strategic initiatives for growth despite a revenue decline, with notable shifts in product mix contributing to improved gross margins.
Key takeaways
- Q3 2025 revenue decreased to $30.3 million, down 14% year-over-year and 10% sequentially, largely driven by lower LDD sales.
- LAL revenue grew 6% year-over-year, constituting 85% of total revenue, reflecting strong demand and engagement from ophthalmologists.
- Gross margin improved significantly to 79.9%, benefiting from a higher percentage of LAL sales and reduced unit costs.
- The company narrowed its full-year revenue guidance to $125 million to $130 million, indicating a cautious but optimistic outlook.
- Cash reserves remained stable at $227.5 million, providing a solid foundation for ongoing strategic initiatives and growth plans.